Ferocit TR150 mg+0.5 mg

Ferocit TR is a combination hematinic (iron + folate) preparation used for the following indications, classified by strength of evidence:

Established / Guideline-supported uses

• Prevention and treatment of iron-deficiency anemia with concurrent folate deficiency, such as occurs from inadequate dietary intake, increased physiological demand, or chronic blood loss.
• Antenatal (prenatal) supplementation during pregnancy, per WHO and obstetric guidance, to reduce the risk of maternal anemia and to support fetal neural tube development. This is the most common and best-supported use of Ferocit TR.
• Prevention of nutritional anemia in women of reproductive age, particularly in populations with high prevalence of iron and folate deficiency.

Adjunct use

• As an adjunct to dietary correction and treatment of the underlying cause of anemia (e.g., menorrhagia, malabsorption, poor nutrition) rather than as a substitute for identifying and managing that cause.

Ferocit TR is not indicated for anemias not due to combined iron and folate deficiency, such as anemia of chronic disease, vitamin B12 deficiency (pernicious anemia), thalassemia, or hemolytic anemia unrelated to iron deficiency; a physician should confirm the underlying cause of anemia before starting therapy.

Each tablet/capsule of Ferrous Sulfate + Folic Acid typically contains:

• Ferrous Sulfate, providing a defined amount of elemental iron (commonly formulated to deliver approximately 60 mg elemental iron per unit dose)
• Folic Acid, typically 350–500 mcg (0.35–0.5 mg) per unit dose, though some formulations use lower or higher amounts depending on the intended indication (e.g., 400 mcg for prophylaxis)

Exact strengths vary by manufacturer and product; always check the specific product label/package insert for the precise composition of the Ferrous Sulfate + Folic Acid product dispensed.

Ferocit TR is a fixed-dose combination medicine that pairs an iron salt with a B-vitamin (folate) to address the two most common nutritional causes of anemia together. Ferrous sulfate supplies elemental iron needed for hemoglobin synthesis and correction of iron-deficiency anemia, while folic acid is required for DNA synthesis and normal red blood cell maturation, correcting folate-deficiency (megaloblastic) anemia and reducing the risk of fetal neural tube defects when taken before and during early pregnancy.

Ferocit TR is widely used as a single, convenient combined supplement rather than prescribing iron and folic acid separately, and is a mainstay of antenatal micronutrient supplementation programs recommended by the World Health Organization (WHO).

Ferocit TR belongs to the Hematinics (Antianemic preparations) — Iron salts in combination with folic acid therapeutic class.

Mechanism of Action

Ferrous Sulfate + Folic Acid works through the complementary actions of its two components:

• Ferrous sulfate dissociates in the gastrointestinal tract to release ferrous (Fe2+) iron, which is absorbed primarily in the duodenum and proximal jejunum. Absorbed iron is transported bound to transferrin and incorporated into hemoglobin in developing erythroblasts, restoring hemoglobin synthesis and replenishing depleted iron stores (ferritin) in iron-deficiency anemia.
• Folic acid is converted to its active metabolite, tetrahydrofolate, which acts as a coenzyme in one-carbon transfer reactions required for purine and pyrimidine (DNA) synthesis. Adequate folate is essential for normal, rapid cell division in erythropoiesis; deficiency causes megaloblastic anemia with large, immature red cells. Folate is also critical for neural tube closure in the early embryo.

Pharmacokinetics

Iron absorption from ferrous sulfate is enhanced by an acidic gastric environment and vitamin C, and is reduced by food, antacids, and certain other drugs (see Interactions). Absorbed iron is stored as ferritin/hemosiderin and eventually incorporated into hemoglobin, myoglobin, and iron-containing enzymes. Folic acid is well absorbed from the small intestine, converted to its active form primarily in the liver and intestinal mucosa, and excreted mainly in urine, with some biliary/fecal loss.

Take Ferocit TR by mouth, ideally on an empty stomach with water for best iron absorption. If stomach upset occurs, it may be taken with a small amount of food (avoiding dairy products, tea, or coffee, which reduce iron absorption). Do not take Ferocit TR at the same time as antacids, calcium supplements, or the interacting drugs listed below; separate dosing by at least 2 hours. Vitamin C-containing foods or juices may enhance iron absorption when taken together.

Ferocit TR has several clinically significant drug interactions, mainly related to its iron component:

• Tetracyclines and fluoroquinolone antibiotics (e.g., doxycycline, ciprofloxacin): Iron chelates with these antibiotics, substantially reducing absorption of both the antibiotic and iron. Separate administration by at least 2–3 hours.
• Levothyroxine: Iron reduces levothyroxine absorption, which may reduce its efficacy. Separate dosing by at least 4 hours.
• Bisphosphonates (e.g., alendronate): Absorption of bisphosphonates is reduced by iron; take at different times.
• Penicillamine: Iron reduces penicillamine absorption; separate dosing.
• Antacids, H2-receptor blockers, and proton pump inhibitors: Reduce gastric acidity needed for iron absorption, lowering iron bioavailability; separate dosing where possible.
• Phenytoin, phenobarbital, primidone: The folic acid component may reduce serum levels of these anticonvulsants (by inducing their metabolism), potentially reducing seizure control; monitoring may be needed.
• Methotrexate: Folic acid may interfere with the antifolate action of methotrexate when used at chemotherapeutic doses; use with caution and only as directed by the treating physician.

Inform your physician of all medicines you are taking before starting Ferocit TR.

Side effects of Ferocit TR are mainly gastrointestinal and attributable to the iron component:

• Common: Nausea, epigastric discomfort/pain, constipation, diarrhea, and dark or black-colored stools (a harmless effect of unabsorbed iron).
• Less common: Vomiting, heartburn, and teeth staining with liquid formulations (rinse mouth/brush teeth after dosing to minimize).
• Rare: Allergic hypersensitivity reactions (rash, itching); folic acid is generally very well tolerated and rarely causes side effects at recommended doses.

Taking Ferocit TR with a small amount of food (rather than on a completely empty stomach) can reduce gastrointestinal side effects, though this may modestly reduce iron absorption. Contact a physician if side effects are severe or persistent.

Ferocit TR is a standard, WHO-recommended combination for antenatal (during pregnancy) micronutrient supplementation, and is widely regarded as beneficial and appropriate for use in pregnancy to prevent maternal anemia and support fetal neural tube development, when taken at the recommended dose. However, dosing should still be individualized and physician-guided, particularly for anemia treatment doses (as opposed to standard prophylactic doses), and iron overdose should be avoided.

Ferocit TR is generally considered compatible with breastfeeding at recommended doses, as both iron and folic acid are normal nutrients; however, a physician or lactation specialist should be consulted regarding the appropriate dose during lactation.

Use Ferocit TR with caution in the following situations:

• Gastrointestinal disorders such as peptic ulcer disease, ulcerative colitis, regional enteritis, or diverticulitis, where iron may aggravate symptoms.
• Undiagnosed anemia: Folic acid supplementation may mask the hematologic (blood count) improvement of undiagnosed vitamin B12 deficiency (pernicious anemia) while allowing progressive, potentially irreversible neurological damage to continue; the underlying cause of anemia should be established before starting therapy.
• Iron overload risk: Avoid unnecessary or excessive use, particularly in patients with a family history of hemochromatosis or repeated blood transfusions.
• Accidental pediatric ingestion: Keep out of reach of children — iron-containing products are a leading cause of accidental poisoning fatality in young children (see Overdose).
• Do not self-medicate for anemia without medical confirmation of the cause; treat the underlying condition (e.g., blood loss source) as well as the deficiency.

Overdose of Ferocit TR, particularly the iron component, is a serious medical emergency and can be fatal, especially in young children who may ingest tablets accidentally. Symptoms of acute iron overdose can include nausea, vomiting (sometimes bloody), abdominal pain, diarrhea, lethargy, and in severe cases, gastrointestinal bleeding, metabolic acidosis, shock, liver damage, and cardiovascular collapse, sometimes after a deceptive period of apparent improvement.

If overdose of Ferocit TR is suspected, seek immediate emergency medical attention or contact a poison control center right away — do not wait for symptoms to appear. Keep the product container available to show healthcare providers. Do not attempt home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

No specific dose adjustment is generally established for Ferocit TR in renal impairment; however, iron and folate status should be monitored, and use should be guided by a physician, particularly in patients with chronic kidney disease who may already be receiving iron therapy as part of anemia management.

Hepatic Impairment

Use with caution in significant liver disease, where iron overload can worsen hepatic injury; physician supervision is advised.

Elderly

No specific dose reduction is generally required, but elderly patients may be more prone to constipation and other gastrointestinal side effects from the iron component; monitor accordingly.

Pediatric

See Pediatric Uses section — only age/weight-appropriate formulations should be used, under medical supervision.

Duration of Ferocit TR therapy depends on the indication:

• Antenatal prophylaxis: Typically continued throughout pregnancy, as advised by the treating physician (and sometimes into the postpartum period per local guidance).
• Treatment of confirmed iron/folate-deficiency anemia: Usually continued for 3 to 6 months after hemoglobin levels return to normal, to replenish depleted iron stores; the exact duration should be determined by a physician based on follow-up blood tests.

Do not stop or extend treatment without medical advice, and complete the full course recommended by your physician even if you feel better before it is finished.

Hematinics; Iron salts (ferrous sulfate) in fixed-dose combination with folic acid (vitamin B9); Antianemic preparations.

Ferrous Sulfate + Folic Acid acts through two complementary mechanisms: ferrous sulfate supplies elemental iron that is absorbed in the small intestine and incorporated into hemoglobin, correcting iron-deficiency anemia and replenishing body iron stores; folic acid is converted to its active coenzyme form and supports DNA synthesis required for the rapid cell division of developing red blood cells, correcting folate-deficiency (megaloblastic) anemia and supporting normal fetal neural tube development when used during early pregnancy.

Ferocit TR is used in children and adolescents only under medical supervision for confirmed iron-deficiency anemia with concurrent folate deficiency, using age- and weight-appropriate pediatric formulations and doses determined by a pediatrician — adult-strength tablets should not be given to young children. Safety and efficacy of specific fixed-dose Ferocit TR combination products have not been formally established in infants and young children outside of physician-directed anemia treatment, and iron-containing products pose a significant accidental-poisoning risk in this age group; all products must be stored strictly out of reach of children.